Thymidylate synthase protein expression in primary colorectal cancer: Lack of correlation with outcome and response to fluorouracil in metastatic disease sites

Journal of Clinical Oncology

Volumn 21, Issue 5, 2003, Pages 815-819

  Johnston, Patrick G ^a   Benson III, Al B ^a   Catalano, Paul ^a   Rao, M Sambasiva ^a   O'Dwyer, Peter J ^a   Allegro, Carmen J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AVIDIN; BIOTIN; ENZYME ANTIBODY; FLUOROURACIL; FOLINIC ACID; THYMIDYLATE SYNTHASE; ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; ASPARTIC ACID; DRUG DERIVATIVE; PHOSPHONOACETIC ACID; SPARFOSIC ACID; TUMOR MARKER;

ANTIBODY LABELING; ARTICLE; CANCER LOCALIZATION; CANCER RECURRENCE; COLORECTAL CARCINOMA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; ADENOCARCINOMA; AGED; COLORECTAL TUMOR; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; ENZYMOLOGY; FEMALE; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARTIC ACID; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; IMMUNOENZYME TECHNIQUES; INTERFERON ALFA-2A; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHOSPHONOACETIC ACID; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0037364351     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.07.039     Document Type: Article

References (21)

1. Johnston PG, Allegra CJ: Colorectal cancer biology: Clinical implications. Semin Oncol 22:418-432, 1995
2. Danenberg PV: Thymidylate synthase: A target enzyme in cancer chemotherapy. Biochim Biophys Acta 473:73-92, 1997
3. Grem, JL: Fluorinated pyrimidines, in Chabner BA, Collins, JM (eds): Cancer Chemotherapy, Principles and Practice. Philadelphia, PA, Lippincott, 1990, pp 180-224
4. Johnston PG, Drake JC, Trepel J, et al: The immunological quantitation of thymidylate synthase using the monoclonal antibody TS106 in 5-FU sensitive and resistant human cancer cell lines. Cancer Res 52:4306-4312, 1992
5. Washtein WL: Increased levels of thymidylate synthase in cells exposed to fluorouracil. Mol Pharmacol 25:171-177, 1984
6. Jackman AL, Kelland LR, Kimbell R, et al: Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. Br J Cancer 71:914-924, 1995
7. Drake JC, Allegra CJ, Moran RG, et al: Resistance to Tomudex (ZD1694) multifactorial in human breast and colon carcinoma cell lines. Biochem Pharmacol 51:1349-1355, 1996
8. Johnston PG, Fisher ER, Rockette HE, et al: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12:2640-2647, 1994
9. Lenz H-J, Danenberg KD, Leichman CG, et al: p53 and thymidylate synthase expression in untreated stage II colon cancer: Associations with recurrence, survival and site. Clin Cancer Res 4:1227-1234, 1998
10. Leichman CG, Lenz H, Leichman L, et al: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infused fluorouracil and weekly leucovorin. J Clin Oncol 15:3223-3229, 1997
11. Johnston PG, Lenz HJ, Danenberg KD, et al: Thymidylate synthase protein and gene expression predicts for response to 5-fluorouracil leucovorin chemotherapy in patients with colorectal and gastric cancer. Cancer Res 55:1407-1412, 1995
12. Chu E, Grem JL, Johnston PG, et al: New concepts for the development and use of antifolates. Stem Cells 14:41-46, 1996
13. O'Dwyer PJ, Manola J, Valone FH, et al: Fluorouracil modulation in colorectal cancer: Lack of improvement with N-phosphonoacetyl-L-aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule. An Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study. J Clin Oncol 19:2413-2421, 2001
14. Paradiso A, DeLena M, Stea B, et al: Thymidylate synthase and p53 primary tumor expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 82:560-567, 2000
15. Marsh S, McLeod HL: Thymidylate synthase pharmacogenomics in colorectal cancer. Clin Colorectal Cancer 1:175-178, 2001
16. Aschele C, Debernardis D, Tunesi G, et al: Thymidylate synthase protein expression in primary colorectal cancer compared with corresponding distant metastases and relationship to clinical response to 5-fluorouracil. Clin Cancer Res 6:4797-4802, 2000
17. Gorlick R, Metzger R, Danenberg KD, et al: Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared to hepatic metastases of colorectal adenocarcinoma. J Clin Oncol 16:1465-1469, 1998
18. Cascinu S, Aschele C, Barni S, et al: Thymidylate synthase protein expression in advanced colon cancer: Correlation with site of metastases and clinical response to leucovorin modulated bolus 5-fluorouracil. Clin Cancer Res 5:1996-1999, 1999
19. Findlay MP, Cunningham D, Morgan G, et al: Lack of correlation between thymidylate synthase levels in primary colorectal cancer and subsequent response to chemotherapy. Br J Cancer 75:903-909, 1997
20. Allegra CJ, Parr Al, Wold LE, et al: Investigation of the prognostic and predictive value of thymidylate synthase, p53, Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 20:1735-1743, 2002
21. Jansson A, Sun X-F: Bax expression decreases significantly from primary tumor to metastasis in colorectal cancer. J Clin Oncol 20:811-816, 2002